Exclusive Summary

• Robust Global IP Protection: Patent protection granted in major markets (US, China, EU, Japan) valid until 2040, securing long-term market exclusivity for partners.
• Differentiated Efficacy for Unmet Needs: Excellent Blood-Brain Barrier (BBB) permeability positions it as a potential Best-in-Class therapy for Glioma, outperforming first-generation inhibitors.
• Superior De-risked Safety Profile: Wider therapeutic window with no hERG potassium channel inhibition significantly reduces late-stage clinical development risks and cardiac safety concerns.

Asset Materials

Contact Us for Full Materials